Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Sezary Syndrome 3Lymphoma, T-Cell, Peripheral 3Leukemia-Lymphoma, Adult T-Cell 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Mycosis Fungoides 2Lymphoma, T-Cell, Cutaneous 2Neoplasms 1Lymphoma, T-Cell 1Lymphoma, Large B-Cell, Diffuse 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1Carcinoma 1Advanced/Metastatic Solid Tumors 1Advanced Solid Tumors 1

Interventions

tislelizumab 4talazoparib 4pembrolizumab 4Docetaxel 4Nivolumab 3PM 01183 2MLN 8237 2Itraconazole 2Fluorouracil 2Cisplatin 2Carboplatin 2zimberelimab 1utomilumab 1urelumab 1ulixertinib 1trifluridine tipiracil drug combination 1sitravatinib 1sapanisertib 1pexidartinib 1pevonedistat 1peposertib 1niraparib 1mogamulizumab 1lenvatinib 1ixabepilone 1eribulin 1durvalumab 1dalotuzumab 1avelumab 1ascrinvacumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Advanced Solid Tumors × mogamulizumab × Clear all
NCT02281409 2021-04-23

Safety, Tolerability, and Immunoregulatory Activity of Mogamulizumab (KW-0761) in Subjects With Advanced and/or Metastatic Solid Tumors

Memorial Sloan Kettering Cancer Center

Phase 1/2 Completed
17 enrolled 13 charts
Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡